Bolt Biotherapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $0.00.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.00K.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $0.00.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $0.00.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $6.00K, a 95.56% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $135.00K, a 77.94% decline from fiscal 2021.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $612.00K, a 287.34% increase from fiscal 2020.
- Bolt Biotherapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $158.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $6.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $6.00K 10-Q · filed 2024-08-13 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $135.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $410.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $28.00K 10-Q · filed 2023-08-07 | $595.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $107.00K 10-Q · filed 2023-05-11 | $590.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $612.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $185.00K 10-Q · filed 2022-11-10 | $415.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $23.00K 10-Q · filed 2022-08-10 | $271.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $129.00K 10-Q · filed 2022-05-12 | $253.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $158.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $41.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $5.00K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $34.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |